Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis
| Autor: | Craig Dietz, Giuliano Rizzardini, Christine Zurawski, Keikawus Arastéh, Dennis Pontani, Will Garner, Thai Nguyen, Jose R. Arribas |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
education.field_of_study business.industry Cobicistat Population Public Health Environmental and Occupational Health Subgroup analysis Lopinavir Emtricitabine Gastroenterology Atazanavir Regimen Infectious Diseases Internal medicine medicine Poster Sessions – Abstract P273 business education Darunavir medicine.drug |
| Zdroj: | Journal of the International AIDS Society |
| ISSN: | 1758-2652 |
| DOI: | 10.7448/ias.17.4.19805 |
| Popis: | Introduction : Simplification to Stribild (STB) was statistically superior to continuation of a ritonavir-boosted protease inhibitor (PI+RTV) with emtricitabine and tenofovir DF (FTC/TDF) at week (W) 48 in virologically suppressed HIV adults (1). We report the W48 efficacy and safety of STB versus RTV-boosted darunavir (DRV) with FTC/TDF in suppressed subjects. Materials and Methods : Virologically suppressed subjects on PI+RTV with FTC/TDF regimens for ≥6 months were randomized (2:1) to switch to STB vs continue their PI regimen. Eligibility criteria included no documented resistance to FTC and TDF, no history of virologic failure and eGFR ≥70 mL/min. The primary endpoint was the proportion of subjects in the modified ITT population who maintained HIV-1 RNA |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|